Julie Heverly describes one harrowing day when her glucose levels teetered between way too high and way too low and how she navigated this challenge.

diaTribe’s Community Manager Cherise Shockley led an online discussion about Time in Range with Shay Webb, a diabetes advocate, and Julia Blanchette, a diabetes care and...

The Association of Diabetes Care and Education Specialists 2021 conference covered the impacts of diabetes stigma, smart MDI therapies, insulin delivery by means other...

How many people have type 1? What are the barriers to using new therapies? What outcomes matter beyond A1c?

Tripling my carbs --> 5 fewer hours in-range per day, 64% more insulin (!), & more lessons learned.

The artificial pancreas is here for those willing to build their own; what can manufacturers learn from OpenAPS?

Strong results from the IMPACT study in low-A1c users.

Highlights from the first study of a commercial automated insulin delivery device. Plus, Medtronic’s latest software updates!

What does A1c miss and what can we do about it?

Coming to US in Spring 2017: What it is, what it isn’t, and how to get it

What does donated diabetes data tell us about time-in-range across different age groups?

Get weekly email and phone notifications summarizing time-in-range and glucose trends from the updated Dexcom Clarity app

The diaTribe Foundation convenes key diabetes experts to discuss glycemic outcomes beyond A1C on July 21, 2017, in Bethesda, MD

Farxiga and Sotagliflozin are the first pills to seek approval as add-ons to insulin for type 1; both bring strong time-in-range benefits, and if approved, might launch...

The world’s first all-diabetes professional cycling team is now sponsored by Dexcom; diabetes research studies on CGM and exercise will start this year: What is the...

Using time-in-range to assess risk for complications, Omnipod Horizon Closed Loop, Bihormonal closed loop (insulin + Pramlintide), SGLT-2 oral drug for type 1, and more!

The most promising therapies in the pipeline, accuracy data on the FreeStyle Libre 2, and more

The latest updates on time-in-range goals for people with all types of diabetes, and insights linking FreeStyle Libre scanning frequency to outcomes.

The benefits of measuring time in range, plus new care guidelines for adults with type 2 diabetes

Control-IQ hybrid closed loop coming in summer 2019; paired app coming soon to the US; plans for the t:sport “patch” pump; and t:slim X2 pump launched outside the US